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1. Introduction 
Chronic kidney disease is a public health problem and one of the outstanding causes of 
death in the industrialized world. The most serious condition is advanced chronic renal 
failure requiring replacement therapy by dialysis or kidney transplantation. In recent years 
the incidence is stabilizing but the prevalence is increasing probably due to the progressive 
aging of the population and increased comorbidity with other chronic disorders such as 
diabetes mellitus, hypertension and obesity (de Francisco et al. 2007). It is also a major cause 
of anemia in developing countries (Maiz, Abderrahim, and Zouaghi 2002) . The long-term 
survival and good quality of life of patients with chronic renal failure depends, among other 
factors, on hemoglobin, iron status and bone marrow response to erythropoiesis stimulating 
agents (ESA). Anemia is an almost constant complication of advanced renal failure which 
may contribute to worsen preexisting heart disease and, as a consequence, accelerate the 
progression of renal dysfunction (Kuwahara et al. 2011), (Silverberg et al. 2009). The 
administration of erythropoietin to patients with kidney and heart failure improves both 
processes, not only increasing hemoglobin but also by a direct effect of erythropoietin on 
cardiac function (Belonje, de Boer, and Voors 2008). In general, anemia is normocytic, 
normochromic and usually well tolerated until the advanced stages of kidney disease. It is 
usually a complication of stage 3 chronic kidney disease (KDOQI and National Kidney 
Foundation 2006). Its etiology is multifactorial: shortening of life span of erythrocytes, 
presence of inhibitors of erythropoiesis in plasma, inadequate production of endogenous 
erythropoietin (EPO) for the degree of anemia, blood loss, and iron and vitamin 
deficiency(Tsubakihara et al. 2010) (Belonje, de Boer, and Voors 2008), (Chamney et al. 2010). 
The outstanding cause is impaired secretion of erythropoietin due to renal disease, while 
other factors may contribute to its establishment, maintenance or aggravation.  
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The specific treatment of choice for anemia of chronic renal failure is recombinant human 
erythropoietin (rHuEPO), a drug considered a historic milestone since the time of its clinical 
use in 1986 (Winearls et al. 1986), and the major therapeutic advance in anemia of chronic 
renal failure. Erythropoietin remains vital in the treatment of anemia of renal failure, but in 
the coming years could be replaced by new erythropoiesis-stimulating agents under 
investigation (Schmid and Schiffl 2010). The use of erythropoietin led to a drastic reduction 
of transfusions and androgen therapy with the consequence of decreasing the complications 
of these treatments. Suitable doses of the drug, as well as the correction of other contributing 
factors to anemia, are necessary to maintain adequate levels of hemoglobin in the range of 
11-12 g / dl (KDOQI 2007). 
Iron is an essential factor to achieve and maintain effective erythropoiesis in patients with 
chronic renal failure treated with rHuEPO, due to frequent losses of blood in the 
hemodialyzer, overstimulation of erythropoiesis induced by erythropoietin and possible 
gastrointestinal bleeding. Moreover, the renal disease itself and chronic inflammation can 
sequester iron in the mononuclear phagocytic system preventing its use for erythropoiesis. 
These factors as a whole significantly increase the demand for iron. Capacity of intestinal 
iron absorption in these patients is not enough to maintain adequate levels of iron stores. On 
the other hand, the supply of iron improves response to rHuEPO and aids to lower its dose 
up to 30%. However, iron administration must be handled with caution, as an excess is not 
safe. The body has mechanisms to regulate iron absorption in the gastro-duodenal tract, but 
lacks a physiological mechanism to remove excess iron. Therefore treatment with 
intravenous iron should be monitored carefully. 
Other causes of anemia in dialysis patients such as: hemolysis, aluminum intoxication, 
infection, chronic inflammation and hyperparathyroidism should not be overlooked; on the 
contrary the anemia of renal failure is not generally characterized by a lack of folic acid or 
vitamin B12 (Bravo, Galindo, and Bienchy 1994). 
For all these reasons, patients need iron administration (usually intravenous) and regular 
monitoring of iron body stores. The diagnosis and treatment protocols should be optimized 
to adjust the cost, improve quality of life and prolong survival, as it has recently been 
reported that patients with hemoglobin above 12 g / dl have a higher survival rate than 
those with lower levels (Pollak et al. 2009). 
The evaluation of anemia and iron status in chronic renal failure has peculiarities that make 
it different from other processes. Therefore we find it useful to include a brief description of 
the normal values in adults, the diagnosis of iron deficiency in general and the peculiarities 
of the diagnosis of iron status in patients with chronic renal failure. The World Health 
Organization specifies the normal range of hemoglobin and defines anemia as a hemoglobin 
decrease below the normal lower limit (Nutritional anaemias (Anonymous1968). 
Hematology analyzers measure the hemoglobin directly, with great precision and accuracy, 
while the hematocrit is a calculated value. Moreover hemoglobin remains constant from the 
extraction of blood until it is analyzed, while the hematocrit increases with time due to 
changes in erythrocyte volume (Tsubakihara et al. 2010). However some publications rely on 
hematocrit as an indicator of anemia, thus we consider both parameters. Red cell indices are 
very useful in the diagnosis of anemia whatever the etiology, and parameters of iron 
metabolism are essential for the diagnosis of iron deficiency anemia. Here we only state the 
normal range for adults of both sexes, excluding infants, children and pregnant women.  
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Below we present laboratory data useful for the study of iron deficiency anemia in general 
and the specific laboratory tests to evaluate iron status in chronic renal failure and 
hemodialysis patients. 
1.1 Red blood cells: Normal values in adults 
Hemoglobin: ♂: 14-17 g / dl; ♀: 12-14 g / dl 
Hematocrit: ♂: 42-52% ♀: 36-46% 
Red cell indices: mean corpuscular volume (MCV) 81-99 fl; 
mean corpuscular hemoglobin (MCH), 27-31 pg; mean corpuscular hemoglobin 
concentration (MCHC) 34 ± 2 g/ dl 
Reticulocytes: ♀: 0.4 to 2.4%, ♂: 0.6 to 2.6%; in absolute numbers: 40 - 100 x 109 / l 
1.2 Assessment of normal iron status in adults 
Serum iron: ♂ and ♀ postmenopausal 50-150 mg/dl; ♀ reproductive age 35-140 mg/ dl 
Transferrin: 200-350 mg/dl 
Transferrin saturation ( serum iron x 100/ transferrin): 30%  
Serum ferritin: ♂ and ♀ postmenopausal 30-400 ng/ml; ♀ reproductive age 15-150 ng/ml 
Absence of iron stores in patients not on dialysis <10-15 ng/ml  
Iron overload > 800 ng/ml. High levels of serum ferritin must be interpreted with caution in 
the clinical setting of tumors, inflammation and chronic conditions because ferritin may be 
elevated even if iron stores are normal or low. In these cases the soluble transferrin receptor 
is useful in estimating iron deposits. Normal levels of soluble transferrin receptor 0.8 to 1.8 
ng /l. 
1.3 Diagnosis of iron deficiency anemia 
In patients without renal impairment, the diagnosis of iron deficiency anemia is based on 
the assessment of Hb (♂ <13 g/ dl and ♀ <12 g/ dl) and hematocrit (♂ <42% ♀ <36%) along 
with a decrease in mean corpuscular volume (MCV <80fl) mean corpuscular hemoglobin 
(MCH <25 pg) and mean corpuscular hemoglobin concentration (MCHC <32g/dl). 
The diagnosis of iron deficiency anemia also requires a reduction of serum iron below the 
following levels: (♂ and ♀ postmenopausal (<50 mg / dl) and ♀ reproductive age (<30 mg / 
dl), increased transferrin (> 360 mg / dl) decrease saturation of transferrin (<20%) and 
decreased serum ferritin (♂ and ♀ postmenopausal <30 ng / ml and ♀ reproductive age <15 
ng / ml), all of them may be complemented by an increase in soluble transferrin receptor (> 
2 ng /l). 
1.4 Diagnosis of iron deficiency in chronic renal failure  
In chronic kidney disease 60-80% of cases have absolute or functional deficiency of iron, 
especially in haemodialysed patients.  
The European Best Practice Guidelines (EBPG) and the Kidney Disease Outcomes Quality 
Initiative (EBPG K / DOQI) have specified slightly different criteria for diagnosis of anemia 
in patients with chronic renal failure (Tsubakihara et al. 2010). 
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With respect to hemoglobin (Hb): 
♂ Hb <13.5 g / dl (EBPG) and Hb <13.5 g / dl (K / DOQI) 
♀ Hb <11.5 g / dl (EBPG) and Hb   12.0 g / dl (K / DOQI) 
> 70 years old Hb <12 g / dl (EBPG) 
With respect to hematocrit, values differ by sex, race and age, decreasing values with 
increasing age, like hemoglobin. The reference values to define anemia by hematocrit in 
Japanese adult males are <40% and in adult women ♀ <35%(Tsubakihara et al. 2010)  
If MCV is decreased or normal the most probable diagnosis is iron deficiency anemia, 
nevertheless other less frequent diagnoses must be ruled out such as: anemia of chronic 
disease, sideroblastic anemia, thalassemia, hemolytic anemia, aplastic anemia, 
myelodysplastic syndrome and pure red cell aplasia. The latter, though extremely rare has 
been associated with erythropoietin therapy, mainly if administered subcutaneously. On the 
contrary if the MCV is elevated macrocytic anemia should be considered due to deficiency 
of vitamin B12 and / or folic acid, liver disease, hypothyroidism, aplastic anemia, 
myelodysplastic syndrome or drugs that interfere with DNA synthesis.  
The traditional parameters of iron metabolism, which are used for the diagnosis of iron 
deficiency in chronic kidney disease, are: serum iron <40 mg / dl, transferrin saturation < or 
= 20%, ferritin < or = 100 ng / ml and Hb <11 g / dl.(KDOQI and National Kidney 
Foundation 2006).  
1.5 New red cell indices and iron status markers – Advantages over traditional 
markers 
The anemia of chronic renal failure is complex and multifactorial, hence the analysis of 
individual parameters is neither accurate nor does it provide a predictive value to determine 
which patients will respond to therapy. This has led in recent years to the publication of 
numerous studies to find new laboratory tests that can identify patients with absolute or 
functional iron deficiency, in order to individualize and improve treatment. These 
parameters as well as others not related to the diagnosis of anemia have also been used to 
try to predict response to treatment with iron and erythropoietin. 
Serum ferritin is not a good index for estimating iron deposits in the course of chronic 
kidney disease ((Kalantar-Zadeh, Kalantar-Zadeh, and Lee 2006). However on the other 
hands serum ferritin is useful for monitoring iron therapy in chronic kidney disease 
((Nakanishi et al. 2010). To overcome drawbacks of ferritin as an estimator of iron stores 
several authors have studied the usefulness of soluble transferrin receptor with discrepant 
results.(Chang et al. 2007) have found a good correlation between the increase in soluble 
transferrin receptor and decreased iron stores. However (Gupta, Uppal, and Pawar 2009, 96-
100) have not found any utility in transferrin soluble receptor as a marker of iron deficiency 
in patients with renal failure. In this context (Chen, Hung, and Tarng 2006a) studied the TfR-
F index calculated by the ratio of transferrin receptor and the logarithm of serum ferritin, 
concluding that it is more sensitive than transferrin receptor to assess iron stores and may 
guide the IV iron therapy in hemodialysis patients better. 
For over a decade reticulocyte parameters have been used to monitor erythropoiesis in 
various diseases, among which are patients with chronic renal failure and anemia (Remacha 
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et al. 1997). (Agarwal, Davis, and Smith 2008) show that the fraction of immature 
reticulocytes behaves as an indicator of response in the anemia of chronic renal failure. (C.H. 
Fourcade, L. Jary, and and H. Belaouni 1999) have studied the reticulocyte profile under 
both regenerative and hypo regenerative bone marrow conditions. (Maconi et al. 2009) have 
made comparative studies of reticulocyte and erythrocyte parameters in the clinical setting 
of patients with anemia. (Brugnara, Schiller, and Moran 2006) have shown the usefulness of 
hemoglobin content of reticulocytes and red cells: Ret-He and RBC-He (Sysmex XE 2100) 
and CH and CHr (Bayer ADVIA 2120), in the identification of different stages of iron 
deficiency in hemodialysis patients. The correlation of both parameters is good and the 
performance of Ret-He is good for absolute iron deficiency, with an AUC of 0.913 a 
sensitivity of 93.3%, and a specificity of 83.2%. The diagnostic performance of Ret-He is less 
favorable for funcional iron deficiency, as the AUC is low (0.657).  
Others such as (Kalantar-Zadeh et al. 2009), have studied iron metabolism markers and 
parameters of renal osteodystrophy looking for predictors of response to erythropoiesis-
stimulating agents in hemodialysis patients and found that in the long term, low iron stores 
in patients with hyperparathyroidism and high bone marrow turnover are associated with 
hypo-responsiveness to ESA.  
The sensitivity and specificity of some other parameters such as transferrin saturation, 
serum ferritin, hypochromic red cells (% Hypo), reticulocyte hemoglobin content (CHr) and 
soluble transferrin receptor (sTfR) have been published by (Tsubakihara et al. 2010). 
According these authors the most sensitive parameters to detect functional iron deficiency 
are serum ferritin and hypochromic red blood cells while the CHr is more specific. On the 
other hand CHr is the most sensitive parameter to detect iron overload, whereas ferritin (> 
800ng/mL) and hypochromic red blood (<10%) cells are more specific (Tsubakihara et al. 
2010).  
In a multicenter study with participation of 9 hospitals in Europe, ( Zini et al 2006) studied 
the utility of a new analytical parameter, low density hemoglobin, (LDH% Beckman-
Coulter), compared with HCM, in hemodialysis patients with functional iron deficiency and 
concluded that they are useful parameters. The percentage of hypochromic red cells 
(%Hypo) has been incorporated to National Kidney Foundation KDOQI guidelines for 
monitoring recombinant human erythropoietin therapy. (Urrechaga 2010) (Urrechaga 2008) 
find a good correlation between (% Hypo) and low-density hemoglobin (LDH%), Both 
behave as good markers of iron deficiency in different types of anemia (anemia of kidney 
disease, iron deficiency anemia, anemia of chronic disease and beta thalassemia) and are 
equivalent. LDH% is a parameter calculated by a mathematical function based on mean cell 
hemoglobin concentration (MCHC) (Urrechaga 2010) 
The anemia of chronic renal failure is also a chronic disease anemia, and therefore 
parameters such as IL6, TNF-alfa and other proteins such as neopterin, hepcidin and 
hemojuvelin should be evaluated. In this context (van der Putten et al. 2010 recently set out 
the clinical role of changes in hepcidin levels and response to treatment with EPO in patients 
with inflammation and renal and cardiac damage. Previously (Zaritsky et al. 2009) propose 
hepcidin as a new biomarker of iron status in chronic kidney disease. Moreover, pro-
hepcidin has been proposed as a useful parameter in the evaluation of iron status in chronic 
kidney disease (Barrios, Espinoza, and Baron 2010; Arabul et al. 2009; Shinzato et al. 2008) 
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2. Objectives 
This trial evaluates a treatment protocol for patients with anemia of chronic kidney disease 
on hemodialysis 
It has two objectives:  
a. To find new predictors of response 
b. To evaluate a combined treatment regimen with EPO and iron in terms of safety, 
stability and efficacy. 
Although planned in advance, this work meets the recommendation of Coyne (Coyne 2010) 
(2010) which specifies: “rather than focus on individual products, we should perform trials 
comparing anemia management strategies to assess safety, efficacy, and cost”. 
Hematological 
parameters 
Hb Coulter LH750® 
 RBC, WBC Coulter LH750®
 
HCT, MCV, MCH, MRV, 
MCHC, MPV, MSCV
Coulter LH750® 
 
RET %, RET#, HLR%, 
HLR#
Coulter LH750® 
 IRF Coulter LH750®
 NE %, NE# Coulter LH750®
Iron metabolism Iron COBAS-Integra 400 Roche® Diagnostic  
 Transferrin COBAS-Integra 400 Roche® Diagnostic 
 TSAT COBAS-Integra 400 Roche® Diagnostic 
 Ferritin COBAS-Integra 400 Roche® Diagnostic 
 TfR-F index, sTfR Roche® Diagnostic
 RBC Ferritin, COBAS-Integra 400 Roche® Diagnostic 
 EPO Access 2 Beckman Coulter
 ESR Alifax Beckman Coulter
Inflammation Fibrinogen ACL TOP IL
 CRP High-sensitivity nephelometry. Beckman 
 IL6 Access 2 Beckman Coulter
Vitamins Vit B12, Folate, RBC Folate Access 2 Beckman Coulter
Platelets  Plt Coulter LH750®
 PPV Coulter LH750®
 PDW Coulter LH750®
Liver ALT, GGT, AT III Roche® Diagnostic
Calculated 
parameters 
RPI calculated : (RET% x HCT)/45  
 RSf® 
calculated : MRVMCV  /1000 
 Maf® calculated : Hb x MCV/100
 VHDWf® (MCV x Hgb)/(RDW x 10)
Table 1. Column 2 shows the panel of laboratory tests. These are grouped by category in 
column 1. Column 3 shows the instrumentation used. The tests were done with reagents 
supplied by the manufacturers of the devices, strictly following the operating instructions 
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manual. (CRP= C- reactive protein, EPO= Erythropoietin, ESR = Erythrocyte Sedimentation 
rate) Hb=Hemoglobin, HCT =Hematocrit ,HLR#=High light scatter reticulocytes (absolute), 
HLR%=High light scatter reticulocytes (relative to Hb), IRF=Immature reticulocyte fraction, 
Maf®=Microcytic anemia factor, IL6= Interleukin 6, MCH=Mean corpuscular Hemoglobin, 
MCHC=Mean corpuscular hemoglobin content, MCV=Mean corpuscular volume, 
MPV=Mean platelet volume, MRV=Mean reticulocyte volume, MSCV=Variance of MCV 
measurement, NE#=Neutrophils count (absolute), NE%=Neutrophils %, RBC=Red blood 
cell count, Plt= Platelets count, PPV=Platelet Packed Volume, RET#=Reticulocytes count 
(absolute), RET% = Reticulocytes %, RBC Folate= Intra-Red Blood Cells Folate), RPI= 
Reticulocyte production index , sTfR=soluble Transferrin Receptor, TSAT= Transferrin 
saturation, RBC Ferritin = Intra-Red Blood Cell Ferritin, TfR-F index =Transferrin Receptor-
Ferritin Index (Soluble Transferrin Receptor/log Ferritin), VHDWf= Volumen Hemoglobin 
Distriburion Wide factor, WBC=White Blood Cells count.  
To achieve these goals we used the laboratory data recommended in the 2006 KDOQI guide 
in order to evaluate anemia and iron status: “Complete blood count (CBC) including red blood 
cell indices (mean corpuscular hemoglobin [MCH], mean corpuscular volume [MCV], mean 
corpuscular hemoglobin concentration [MCHC]), white blood cell count, differential and platelet 
count, absolute reticulocyte count, serum ferritin to assess iron stores and serum ferritin and the 
transferrin saturation (TSAT) or content of Hb in reticulocytes (CHr) to assess adequacy of iron for 
erythropoiesis”; as well as other parameters that we feel could be useful in predicting 
response, according to publications mentioned above (see table 1)  
3. Materials, patients and methods 
3.1 Study groups and therapy  
This is a prospective, open, nonrandomized trial. Forty-two patients from the dialysis 
department of the "Hospital Clinico Universitario de Zaragoza" (Spain) have been included. 
Patients were treated by hemodialysis (HD), EPO and Iron. Patients were not transfused 
during the study.  
All patients gave informed consent. We analyzed the parameters specified in Table 1, 
monthly for 6 months. 
In addition hemoglobin, reticulocyte and iron status were evaluated at the 7th month to 
assess response to therapy received during the sixth month. 
3.2 EPO doses 
3.2.1 Initial  
- Pre-dialysis, 40 U / kg once a week 
- Dialysis: 40 U / kg three times a week 
3.2.2 Adjustment  
- Evaluate four weeks later. If Hb increase exceeds 5%: do not change dose, otherwise 
increase 20 U / kg. 
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- Reassess every 4 weeks. Increase 20 U if the rise in hemoglobin is less than 5% 
- Maximum 200 U / kg. 
- Do not abruptly discontinue administration of erythropoietin, unless there is life 
threatening risk. 
The maintenance phase begins when the target is reached (hemoglobin 12g/dl) 
3.2.3 Maintenance 
If the hemoglobin is 12 g / dl or greater decrease the dose of erythropoietin as follows: 
- If the last dose was greater than 80 u / kg, reduced by half. 
- If the last dose was less than 80 U / kg, left as maintenance 30 U / kg. 
3.3 Iron therapy  
3.3.1 Pre-dialysis 
Iron (oral ferrous sulfate) is given to all patients with chronic renal failure non dialyzed with 
hemoglobin less than 11 g / dl or ferritin below 100 ng / mL and transferrin saturation 
below 20%. 
Patients with an inadequate response to oral iron or gastrointestinal intolerance have been 
treated with 200 mg of Intravenous iron sucrose before starting the dialysis program. 
3.3.2 Dialysis 
All patients on dialysis included in this assay were treated with iron sucrose: 100 mg of iron 
sucrose in 100 cc saline in slowly perfusion at the end of each hemodialysis session (three 
times per week) 
3.3.3 Target 
Ferritin levels between 200 – 400 ng/ml and transferrin saturation > 20% 
3.3.4 Adjustment of iron dose  
As shown in table 2 
Conditions Adjustment of iron doses  
If ferritin < 200 ng /ml 100 mg weekly  
If ferritin 200-350 ng / ml 100 mg every 15 days 
If ferritin 350 – 500 ng / ml 100 mg monthly. 
If ferritin > 500 ng /ml Stop iron therapy  
If TfSat > 50% Stop iron therapy regardless of serum ferritin 
Table 2. Schedule for dose adjustment of Iron  
With the exception of 7 patients, 6 laboratory panels per patient (one panel per month) are 
available. Of the 7 patients with missing data 3 died and 4 were transplanted. None of the 
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deaths were related to the treatment with iron or erythropoietin. The laboratory data of 
these patients until death or transplantation were included in the statistical analysis.  
Hemoglobin and iron status were also analyzed one month after the last (6th) panel in order 
to classify patients as responders or non-responders. Finally 224 laboratory panels were 
analyzed.  
4. Definitions and criteria of response 
Most authors only use hemoglobin as a criterion of response. This is correct when 
evaluating a long period of time, but for short periods the response may have started before 
there was an increase in hemoglobin. Therefore we have chosen a target compound in which 
the main data is the increase or maintenance hemoglobin, but giving the option to evaluate 
earlier data of erythropoiesis (reticulocytes and sTfR (Soluble transferrin receptor)) and the 
rise in hemoglobin over two months, instead of evaluating only the change in hemoglobin 
from one month to the next. 
4.1 Criteria  
Response was assumed if one of the following four conditions was fulfilled.  
1. Increase of Hb ≥ 0.5 g/dl in the next control and/or increase of Hb for the following 
two controls > 0.8 g/dL, under condition that both changes are positive. 
2. Achieve or maintain minimum levels of hemoglobin of 11 g/dl in women and 12 g/dl 
in men with the following two conditions: 
3. Hb increase 
4. Ret# >50 x 109/L  
5. Increase of sTfR > 20%, provided that Hb also increases 
6. Increase of Ret#>40 x 109/L provided that Hb also increases. 
As can be seen to increase or maintain hemoglobin at normal levels is a prerequisite. 
However, we reduce the quantitative criteria for hemoglobin if the increase in reticulocytes 
or soluble transferrin receptor suggests an early recovery. Others consider, like us, the 
increase of reticulocytes as one of the criteria of response to erythropoietin (Brugnara, 2003)  
4.2 Definition and classification of iron deficiency status  
Applying the criteria of (Ng et al. 2009, c247-52) patients were divided into 4 groups, whose 
definitions and frequencies are as follows: 
- Group 1. Absolute Iron deficiency. (Ferritin < 100ng/ml and Transferrin Saturation < 
20%): 5  
- Group 2. Functional Iron deficiency. (Ferritin ≥ 100ng/ml and Transferrin Saturation < 
20%): 33 
- Group 3. Ferritin < 100ng/ml and Transferrin Saturation ≥ 20%: 9 
- Group 4. Iron repletion (Ferritin > 100ng/ml and Transferrin Saturation ≥ 20%): 198 
To avoid confusion between functional iron deficiency and iron deficiency, hereinafter the 
latter will be referred to as absolute iron deficiency. 
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5. Statistical analyses  
5.1 Directed at objective A 
All statistical analyses were performed with SPSS.  
All parameters were tested regarding departures from normal distribution by KS-test 
(Kolmogorov-Smirnov). In case of normal distributed parameters, group-wise means and 
standard deviations were calculated. In case of non-normality log transformation or 
description by non-parametric approaches (median, rank-correlation) were used to avoid 
biases related to not normally distributed parameters. All comparisons were performed by 
U-test. For parameters with significant group-wise differences the area under ROC curve 
(AUC) was calculated.  
A correlation matrix (Pearson-correlation, rank-Spearman correlation) of all parameters was 
calculated and evaluated by factor analysis in order to gain information about relationship 
between the parameters and to reach a reduction of dimensions (variables) in subsequent 
statistical analysis (Härdle and Simar 2003) Parameters that were found associated using the 
statistical program were regarded as a parameter-class. 
Bonferroni correction was used to avoid false positive results of significance due to multiple 
testing. The number of components NC resulting from factor analysis was used for 
correction. Starting from a significance level of =0.05, comp=0.05/NC was used for group-
wise comparisons. 
In order to calculate models describing dependence of binary outcome variable (response) 
on parameter values, logistic regression was performed. Parameters ci determined in the 
model can be used in equations of the following type (n-dimensional model for logistic 
regression), where presp is probability of response, Xi is value of blood parameter and ci is 
coefficient for blood parameter Xi within the model: 
 
))..(exp(1
1
110 nn
resp
XcXcc
p 
 
(1) 
In practice, ranges of probability of response between 0 (prediction of no response) and 1 
(prediction of response) can be calculated by putting all parameter values Xi into the 
formula.  
Resulting models were evaluated by ROC analysis and calculating AUC, as mentioned 
above. Furthermore, practical issues like robustness of parameters and ability of a simple 
data management (e.g. avoiding usage of mean differences) were considered.  
In addition cases were separated according to iron status classification and compared by 
univariate two-factor ANOVA (factors: iron status group, response) with post-hoc-
comparisons 
5.2 Statistical analyses directed to objective B  
The descriptive statistics were carried out as follows.  
The first step was to study the evolution of hemoglobin each month using parametric 
(Student) and nonparametric (comparing the overall monthly evolution of hemoglobin by 
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the Kruskall-Wallis test) methods followed by bivariate comparisons of each month with the 
next(Mann-Whitney). Although hemoglobin fits a normal distribution we also used 
nonparametric tests to avoid false positive results due to sample size. In this section we 
choose hemoglobin as the dependent variable, not including any other criteria of response. 
This is because the purpose of this section to compare the parameters with hemoglobin, the 
therapeutic target that really determines the quality of life of patients. 
In a second step we use multiple linear regression to obtain a mathematical model that 
relates the levels of hemoglobin with selected parameters. 
The graphic presentation of hemoglobin evolution over time has been made by Box Plot to 
display the median, interquartile distribution, outliers and overlapping. We have also 
represented the means on a bar graph with confidence interval of 95%. 
Finally we applied the same statistical model to the parameters that quantify the iron status: 
serum iron, transferrin, transferrin saturation, ferritin and soluble transferrin receptor. This 
statistical treatment is aimed to check whether iron treatment regimen is optimal, or 
requires changes.  
6. Results 
6.1 Descriptive statistics and groups 
6.1.1 Demography  
42 patients; gender F: 15, M: 27; age: median: 73 years (range: 22 – 88) 
6.1.2 Responses  
79 responses, 97 non responses, 88 not available (no EPO therapy, transplanted, death or 
missing data. (Table 3). 
 Transferrin Saturation 
< 20% >20% 
Ferritin  
ng/ml 
<100  Group 1(ID) 
5 (2%) 
Group 3 
9 (3.7%) 
>100 Group 2 (FID) 
33 (13.5%) 
Group 4 (IR) 
198 (80.8%) 
Table 3. Distribution of cases according to groups defined by Young and Chun (2009) 
(see text) 
6.1.3 Iron status 
Applying the criteria of Young and Chun (2009) frequencies of the four groups of iron status 
are: 
- Group 1. - Absolute Iron deficiency (ID) (Ferritin < 100ng/ml and Transferrin 
Saturation < 20%): 5  
- Group 2. - Functional Iron deficiency (FID) (Ferritin ≥ 100ng/ml and Transferrin 
Saturation < 20%): 33 
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-  Group 3. - Ferritin < 100ng/ml and Transferrin Saturation ≥ 20% (Iron status is not well 
defined in this group). Transferrin saturation is enough for erythropoiesis, but iron 
stores may be low: 9 
- Group 4. - Iron repletion (IR) (Ferritin > 100ng/ml and Transferrin Saturation ≥ 20%): 198 
6.1.4 Descriptive statistics of all parameters 
The descriptive statistics and comparison with normal distribution is shown in table 4. 
 N Mean SD Median Minimum Maximum
Comparison 
with normal 
distribution 
(Kolmogorov-
Smirnov) 
HLR (%) 189 0.825 0.36 0.836 0.062 2.24 n.s. 
HLR# (n/mm3) 189 28.7 12.5 28.6 1.88 66.7 n.s. 
RPI 189 1.55 0.534 1.59 0.12 3.14 n.s. 
RET (%) 192 2.08 0.735 2.13 0.149 5.05 n.s. 
RET# (n/mm3) 192 72.1 24.5 73.2 9.15 150 n.s. 
IRF 189 0.387 0.0757 0.393 0.16 0.56 n.s. 
Hb (g/dL) 224 11.1 1.44 11.1 7.18 14.8 n.s. 
HCT (%) 192 34 4.33 33.9 21.7 45 n.s. 
RBC 103 / mm3) 195 3490 444 3470 2130 4690 n.s. 
Maf 224 10.8 1.6 11 6.54 14.7 n.s. 
RSf 189 0.11 0.00692 0.11 0.09 0.13 n.s. 
MCV (fL) 224 97.3 4.93 97.6 83.8 113 n.s. 
MSCV (fL) 189 95.9 6.04 95.5 83.5 116 n.s. 
MRV (fL) 189 124 11 124 96.3 165 n.s. 
MCH (g/L) 195 31.8 1.83 32.1 26.8 35.8 n.s. 
EPO (IU/L) 238 21.3 39.6 12 1.75 465 p<0.00001 
sTfRFindex 221 0.755 0.247 0.724 0.282 2.02 n.s. 
sTfR (mg/L) 222 1.82 0.498 1.8 0.8 3.2 p=0.046 
Fibrinogen 
(mg/dl) 
222 521 121 518 246 993 n.s. 
ESR  
(mm/ first hour)
222 43.2 28.2 35.5 1 142 p=0.0038 
CRP (mg/L) 223 1.73 4.78 0.64 0 38.6 p<0.00001 
IL6 (ng/L) 238 10.5 15.3 6.43 0.6 160 p<0.00001 
Ferritin (ng/ml) 223 376 275 326 24.3 2290 p<0.00001 
Plt (103/mm3) 192 213 56 216 92.5 368 n.s. 
PPV (%) 192 0.178 0.0412 0.175 0.0713 0.288 n.s. 
TfSat (%) 223 33.2 12.3 32.2 9.8 82.8 n.s. 
Iron (g/dL) 223 56.7 22.4 53.5 9.87 198 n.s. 
MCHC (g/dl) 192 32.6 0.723 32.6 31 34.8 n.s. 
MPV (fl) 191 8.46 1.07 8.34 6.13 11.4 n.s. 
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RDW (%) 192 15.8 1.47 15.7 13.2 20.9 n.s. 
@NE 192 66.8 8.09 66.6 46.6 83.9 n.s. 
NE# 192 5 1.61 4.79 1.16 9.74 n.s. 
WBC  
(103/ mm3) 
192 7.33 2.2 7.46 0 14.9 n.s. 
VitB12 (pg/ml) 224 534 218 484 180 1180 p=0.025 
RBC Folate 223 723 796 421 107 3670 p<0.00001 
PDW 192 16.7 0.554 16.6 15.6 18.5 n.s. 
ALT (U/L) 222 14.8 12.2 12 1 73 p<0.00001 
GGt (U/L) 222 31.5 38.8 17 4 211 p<0.00001 
RBCFerritin 
(ng/ml of RBC) 
224 731 345 638 223 2160 p=0.00023 
Transferrin 
mg/dl 
223 175 35.7 169 73.8 351 n.s. 
ATIII (% of 
normal control) 
220 101 16.9 101 62 149 n.s. 
Table 4. Descriptive statistics and Kolmogorov-Smirnoff test (n.s. = not significant difference 
from normal distribution)  
All parameters are normally distributed, with the exceptions of Ferritin, EPO, ESR, CRP, 
IL6, Vit B12, RBC, Folate, RBC ferritin, ALT and GGT. In all of these differences with the 
normal distribution are avoided by logarithmic transformation. 
6.1.5 Factorial analysis  
The coefficients given in Table 5 refer to the association of each parameter to one of the 
classes determined by factor analysis. The row-wise maximum relates each parameter to one 
of the 12 classes. Some of the parameters contribute to several components. As an example, 
Maf, which is a product of MCV and Hb, is associated to class 3 (contains Hb) as well as 
class 2 (contains MCV). In a similar manner, WBC is not only associated to Plt and Pct, but 
also to neutrophil-linked parameters NE# and NE%. 
(See Table 5) 
 
Component
1 2 3 4 5 6 7 8 9 10 11 12 
1 
HLR % 0.97     
HLR # 0.97     
RPI 0.94     
RET # 0.94     
RET % 0.93     
IRF 0.65 0.35     
2 
Hb 0.97     
HCT 0.97     
RBC 0.92     
Maf 0.88 0.40     
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VHDW    0.75           
-
0.37         
3 
RSf 0.95     
MCV 0.90     
MRV 0.84     
MSCV 0.84     
MCH     0.81         
-
0.47         
4 
EPO (log) 0.81     
TfR-F index 0.51
-
0.50
-
0.42   
sTfR 0.42
-
0.38
-
0.46   
5 
Fibrinogen 0.83     
ESR (log) 
-
0.33 0.78     
CRP (log) 0.74     
IL6 (log) 0.59 0.43   
Ferritin (log)
-
0.39 0.43 0.40   
-
0.40 
6 
Plt 0.94     
PPV 0.88     
7 
TfSat% 0.84     
Iron 0.73     
8 
MCHC 
-
0.79     
MPV 
-
0.33 0.60     
RDW 0.41 0.55     
9 
NE # 0.35 0.80     
NE % 0.75     
WBC 0.40 0.63     
10 
Vit. B12 (log) 0.77     
RBC Folate 
(log) 0.75     
PDW 
-
0.45
-
0.57     
11 
ALT (log) 0.78   
GGT (log) 0.66   
RBC Ferr. log)
-
0.35 0.49 
-
0.35 
12 
Transferrin   0.84 
ATIII 0.37   0.53 
Table 5. Factor analysis and correlation matrix.  
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Parameters with column maximum-wise (HLR% in case of class 1, Hb in class 2, Rsf® in 
class 3 and so on) are representative of class in the best manner.  
6.1.6 Functional description of classes 
It is worth noting that each of the classes (selected by factor analysis) contain a group of 
parameters that have a common physiological or pathological role. 
 Class 1 is associated with erythropoietic activity: reticulocytes and reticulocyte indices 
 Class 2 is related to parameters that provide information about the absence, presence or 
severity of anemia 
 Class 3 is related to red cell indices and their derivatives obtained by mathematical 
formulas. They report on the type of anemia. 
 Class 4 is associated with stimulation of erythropoiesis 
 Class 5 is associated with chronic inflammatory disease 
 Class 6 reports on platelets  
 Class 7 is associated with iron status 
 Class 8 is associated with microcytosis and anisocytosis.  
 Class 9 reports on neutrophils. 
 Class 10 reports on vitamin deficiency. 
 Class 11 reports on liver disease. 
 Class 12 reports of acute phase reactants not included in class 5. 
6.1.7 Weekly erythropoietin dose and response to treatment 
(See table 6) 
  Response Total  
EPO doses  No response Response  Significance 
 2000 Count 3 2 5 n.s. 
  % 3.1% 2.5% 2.8%  
 3000 Count 3 2 5 n.s. 
  % 3.1% 2.5% 2.8%  
 4000 Count 10 4 14 n.s. 
  % 10.3% 5.1% 8.0%  
 6000 Count 14 11 25 n.s. 
  % 14.4% 13.9% 14.2%  
 8000 Count 20 18 38 n.s. 
  % 20.6% 22.8% 21.6%  
 12000 Count 18 15 33 n.s. 
  % 18.6% 19.0% 18.8%  
 16000 Count 29 27 56 n.s. 
  % 29.9% 34.2% 31.8%  
Total Count 97 79 176 n.s. 
 % 100.0% 100.0% 100.0%  
Table 6. No significant differences were found between the different doses of erythropoietin.  
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6.1.8 Univariate analysis of selected parameters comparing the groups of iron status 
and split by responders and no-responders 
Table 7 shows statistical analyses of all parameters and their relations with the Iron Status 
classification and State of Response. In this analysis the iron status groups: ID, FID and IR 
are only taken into account. The 9 patients in group 3 have been excluded. ANOVA results 
have been compared with those of the Mann-Whitney test because the number of cases in 
each group is unbalanced. The Mann-Whitney, being nonparametric, is less affected by the 
imbalance. Parameters of the same class of those selected by factor analysis, behave 
similarly. Hb, RET# and sTfR show significant differences because they enter into the 
definition of response. 
Parameters with column maximum are those that best represent their class as detailed above 
(material and methods).  
Parameter Iron Status Response  Effect Response via Mann 
Whitney U-Test 
 
Iron Status Response 
status 
Rsf n.s. n.s.    
MCV n.s. n.s.    
MCH n.s. n.s.    
MSCV n.s. n.s.    
MRV n.s. n.s.    
HLR% n.s. n.s.    
HLR# p=0.033 n.s.    
RET% n.s. n.s.    
RET# n.s. n.s.    
RPI p=0.045 n.s.    
IRF p=0.045 n.s.    
Hb p=0.000 p=0.025 ID, FID < IR Resp<nonresp p=0.0028 
HCt p=0.001 p=0.029 ID < IR Resp<nonresp p=0.07 
RBC p=0.002 p=0.033 ID<IR Resp<nonresp p=0.044 
Maf p=0.000 p=0.039 ID < IR Resp<nonresp p=0.014 
Plt n.s. n.s.    
PPV n.s. n.s.    
WBC n.s. n.s.    
TfRFindex n.s. n.s.    
sTfR p=0.085 n.s. ID<IR   
EPO  n.s. p=0.016 FID: Resp<non resp 
IR: Resp>= non resp 
p=0.011 
ESR n.s. n.s.   
CRP p=0.000 n.s. FID > IR, ID  
IL6 p=0.000 n.s. FID > IR,   
MCHC n.s. n.s.  p=0.0007 
MPV n.s. n.s.   
RDW p=0.031 n.s. FID, ID <IR  
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Ferritin p=0.000 n.s. trivial result  
Iron p=0.000 n.s. trivial result  
TSAT p=0.000 n.s. trivial result  
Vit. B12 n.s. n.s.   
RBC Folate n.s. n.s.   
PDW n.s. n.s.   
ALT n.s. n.s.   
GGT p=0.043 n.s. ID, (FID) > IR  
RBC Ferr n.s. n.s.   
NE# n.s. n.s. ID<IR  
NE% n.s. n.s. ID<IR  
Transferrin p=0.000 n.s. trivial result  
AT III n.s. n.s.   
Table 7. Univariate two-factor ANOVA (Iron Status, Response) and Mann-Witney test. 
Significant differences for iron status are shown in column 3, for response status in column 4 
and their effect in column 5. Parameters that enter into the definition of iron stages are 
logically associated with themselves; therefore we specify "trivial result". 
6.1.9 Description of responses to therapy 
Hereafter "case" means each result (6 per patient) for the referred parameter. 
From 42 patients, 83 cases with EPO-treatment were considered as responses (38.6%). 132 
cases (61.4%) were not responding. Among the responses, 40 (18.6% of 215) fulfilled 1 
criterion of response, 36 cases (16.7%) 2 criteria, 5 cases (2.2%) 3 criteria and 2 cases (0.9%) 4 
criteria. The distribution of responses according to the criteria is as follows: 
 Criterion 1. - 63 cases. (Increase of Hb ≥ 0.5 g/dl in the next control and/or increased of 
Hb in the whole of the following two controls > 0.8 g/dL, under condition that both 
changes are positive)  
 Criterion 2. - 48 cases (Achieve or maintain normal Hb for hemodialysis patients (male: 
12 g/dl, female: 11 g/dl) under two conditions: Hb increase and Reticulocytes >50 x 
109/L)  
 Criterion 3. - 17 cases (Increase of sTfR > 20%, provided that Hb also increases)  
 Criterion 4. -7 cases. (Increase of Ret#>40 x 109/L provided that Hb also increases)  
6.1.10 Parameters predicting response  
Table 8 shows the descriptive statistics and the response to combination therapy with iron 
and erythropoietin. We selected three variables (MCHC, EPO and Hb) with the highest 
levels of significance to determine their predictive value on response to therapy.  
AUC of related ROC for these three parameters are respectively: 0.631 (95% CI: 0.54 - 0.70) 
for Hb, 0.612 (95% CI: 0.58 - 0.73) for EPO, and 0.662 (95% CI 0.57 – 0.73) for MCHC as 
shown in Figure 1, 2 and 3. 
AUC of related ROC curves 
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 Non Response Response  
N Mean SD Med Min Max N Mean SD Med Min Max p 
HLR % 78 0.795 0.372 0.803 0.117 2.24 66 0.897 0.332 0.895 0.256 1.57 0.076 
HLR # 78 27.7 12.2 28.4 4.55 66.7 66 30.8 12.4 31.3 7.7 62 0.143 
RPI 78 1.52 0.517 1.62 0.121 3.14 66 1.65 0.535 1.7 0.589 2.84 0.161 
RET % 80 2.05 0.781 2.13 0.149 5.05 67 2.24 0.66 2.31 0.963 3.71 0.067 
RET # 80 71.6 23.4 74.5 19.8 150 67 76.3 24.8 76.2 29 134 0.287 
IRF 78 0.376 0.078 0.388 0.156 0.52 66 0.395 0.0622 0.396 0.225 0.52 0.226 
Hb 97 11.4 1.32 11.3 8.62 14.8 79 10.7 1.54 10.7 7.18 14.5 0.0028 
HCT 79 34.6 3.93 34.3 26.6 45 68 33.3 4.89 33 21.7 44.8 0.0752 
RBC 81 3540 385 3480 2750 4620 69 3410 502 3340 2130 4690 0.0442 
Maf 97 11.1 1.51 11.3 7.86 14.4 79 10.4 1.69 10.5 6.54 13.8 0.0137 
VHDW  79 7.08 1.32 7.4 4.26 9.69 68 6.7 1.28 6.85 4.04 9.61 0.0505 
RSf 78 0.11 0.006 0.11 0.0967 0.12 66 0.11 0.0076 0.11 0.094 0.134 0.744 
VCM 97 97.4 4.63 97.5 83.8 109 79 97.4 5.11 98.1 85.8 109 0.891 
MSCV 78 95.6 5.76 95.3 83.5 116 66 96.2 6.47 95.8 83.9 111 0.506 
MRV 78 124 8.74 124 105 143 66 125 12.3 123 96.3 165 0.785 
MCH 81 31.9 1.77 32.1 26.8 34.8 69 31.5 1.85 32 27.5 35.1 0.261 
EPO  97 11 11.9 8 1.8 78.6 79 18.4 27.6 10.1 1.1 200 0.0107 
TfR-F 
index 
95 0.761 0.249 0.728 0.366 2.02 79 0.759 0.245 0.725 0.282 1.36 0.885 
sTfR 95 1.85 0.495 1.8 1 3.2 79 1.82 0.512 1.8 0.8 3.1 0.752 
Fibri-
nogen 
96 539 128 526 284 993 79 498 110 487 264 836 0.0296 
ESR 97 44.2 29 35 8 125 78 40 27.9 32 3 142 0.309 
CRP 97 1.89 5.5 0.69 0 38.6 79 1.33 2.93 0.64 0.11 24.3 0.552 
IL-6 97 10.7 20.6 6.15 0.75 160 79 8.14 7.48 6.3 0.6 48.5 0.772 
Ferritin 97 379 250 348 24.3 1940 79 344 211 320 33.2 1160 0.296 
Plt 79 214 57 222 114 327 68 212 57.6 210 114 368 0.892 
PPV 79 0.176 0.042 0.173 0.0919 0.27 68 0.178 0.0397 0.177 0.088 0.288 0.718 
TfSat% 97 33.8 12.3 32.3 11.4 82.8 78 32.5 10.9 32.3 12.6 68.5 0.611 
Iron 97 59.6 25.3 54.1 15.7 198 79 54.1 17.7 53.5 12.2 91.9 0.218 
MCHC 79 32.7 0.662 32.7 31.1 34.8 68 32.3 0.665 32.3 31 34 0.0007 
MPV 78 8.29 1.1 8.3 6.13 11.4 68 8.54 1.02 8.3 6.4 11 0.302 
RDW 79 15.8 1.48 15.6 13.3 20.9 68 15.8 1.47 15.7 13.2 20.8 0.864 
NE % 79 65.9 8.37 66.6 46.6 82.4 68 67.1 8.11 65.1 53.6 83.9 0.503 
NE # 79 4.86 1.59 4.63 2.42 9.74 68 5 1.61 4.89 1.16 8.93 0.424 
WBC 79 7.25 2.13 7.03 0 14.9 68 7.21 2.37 7.62 0 14.1 0.546 
Vit B12 97 525 210 482 184 1160 79 527 199 498 191 1180 0.839 
RBC 
Folate 
96 691 804 318 107 3670 79 787 920 388 109 3500 0.38 
PDW 79 16.7 0.612 16.7 15.6 18.5 68 16.6 0.52 16.6 15.6 17.9 0.516 
ALT 96 13.5 9.99 12 1 56 79 15.8 13.5 13 1 73 0.22 
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GGt 96 30 38.5 16 4 201 79 33.1 39.1 19 5 210 0.286 
RBC Ferr. 97 704 310 632 281 1950 79 698 309 583 230 2010 0.735 
Transfer-
rin 
97 174 31.4 169 79.1 280 79 176 41.5 169 73.8 351 0.811 
ATIII 95 102 15.6 103 68 149 78 103 19 104 65 149 0.724 
Table 8. Descriptive statistics of all variables split by response o no response (from month to 
month). Significant differences have been highlighted.  
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Fig. 1. MCHC AUC: 0.662 (0.573 – 0.75) 
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Fig. 2. HB AUC: 0.631 (0.548 – 0.714) 
www.intechopen.com
 
Iron Metabolism 
 
108 
 
1.00.80.60.40.20.0
1 - Specificity
1.0
0.8
0.6
0.4
0.2
0.0
S
e
n
s
it
iv
it
y
 
 
Fig. 3. EPO AUC: 0.612 (0.528 – 0.696) 
6.1.11 ROC curves and AUC 
The area under the curve of each of the three variables is too low to be practical in predicting 
response to treatment. So we tried to make a composite model with more prediction power. 
6.1.12 Prediction model 
Based on these results, several models to predict the response on the basis of parameters 
evaluated in this study have been calculated by logistic regression. The optimal model was 
chosen by achieving maximal AUC with a minimum of parameters and taking into account 
practical issues. The best three-parameter combination was RBC, EPO and MCHC 
(AUC=0.72). RBC, belonging to the same class as hemoglobin, slightly improves the AUC 
(+0.1). For this reason the model includes RBC, EPO and MCHC, instead of HB, EPO and 
MCHC. We could not find any other parameter able to increase the power of the predictive 
model. Figure 4 shows the ROC curve of this composite three parameter model. The AUC is 
0.72 (%95 CI: 0.62 – 0.80). (Fig.4.) 
The related formula is: 
 
      
1
1 23 39 1 327 0 838 0 787
1000
respp RBC
exp( ( . . log(EPO) . MCHC . * ))
 (2) 
This model, being the best, has relative clinical utility because the AUC is not as high as 
would be desirable. 
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Fig. 4. ROC curve of the combination: RBC, EPO and MCHC (AUC: 0.72 (0.619 – 0.791) 
7. Efficacy and safety  
This section not only tries to verify the effectiveness and safety of treatment but also looks 
for correlations between hemoglobin and other variables. These correlations should not be 
interpreted as predictors of response, since hemoglobin is considered as a whole rather than 
month to month as in the previous section. Therefore we try to find a mathematical model to 
predict hemoglobin levels considering all the time of observation as a whole. For this 
purpose we have selected hemoglobin as a dependent variable. We have also selected 
explicative variables that measure the erythropoietic activity (reticulocytes and soluble 
transferrin receptor), indicators of iron status (serum iron, ferritin, transferrin and 
transferrin saturation), other nutritional factors (vitamin B12 and folic acid) and some 
indicators of acute or chronic inflammation (IL-6 and CRP) that can interfere with iron 
metabolism and erythropoiesis. (Table 9) 
Statistical planning of this section is as follows:  
- Descriptive statistics: means and frequencies 
- Comparative evolution of hemoglobin in the 6 months: ANOVA and nonparametric 
- Statistical comparison of patients with hemoglobin <11g/dl versus≥11g/dl: ANOVA, 
equality of variances and robust tests.  
- Multiple linear regression stepwise forward (hemoglobin as dependent variable and all 
others as explicatory).  
- Variables that did not fit the normal distribution have been replaced by their respective 
logarithms in parametric tests. 
7.1 Descriptive statistics  
Descriptive statistics are shown in table 9  
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N Min Max Mean S.D. 
EPO 245 1.75 465.12 23.5789 42.74901 
IL-6 245 .60 375.39 15.3838 39.48357 
CRP 243 .05 38.60 2.0386 4.86809 
Hb 245 7.20 14,8 11.0665 1.54600 
HCT 245 21.40 59.50 33.7563 4.62126 
RETICULOCYTE 244 9.10 150.40 73.8156 24.98430 
Fe 244 9.87 197.61 54.8609 22.59088 
TRANSFERRIN 244 73.79 350.58 174.2232 34.89244 
FERRITINE 244 33.20 2290.00 399.6719 292.31897 
sTfR 244 .70 6.61 1.8598 .60920 
B12 245 180.00 1455.00 541.3102 226.92288 
FOLIC 245 1.60 200.00 27.5331 54.87474 
FOLIC-INTRAE 244 85.50 3667.70 700.0311 770.10104 
TSAT 244 8.54 87.09 31.9443 12.69501 
Table 9. Descriptive statistics of variables used in this section 
7.2 Hemoglobin stability 
As shown in table 10, the means of hemoglobin vary from 10.9 to 11.3 during the six months 
follow-up period and remain always within the desired range. The minima of each month 
correspond to different patients, indicating at least a partial recovery of those who have held 
the minimum in any of the previous months. None of the patients exceeded 15 g / dl of 
hemoglobin as can be seen in the Box-Plot (Graph A1). This graph also shows the extreme 
values, which show only 6 out of a total of 245 samples. The evolution of individual patients 
who have had these outliers can be seen in Graph A-2. 
MONTH Mean (g/dl) N Standard deviation Minimum Maximum 
1 10.9689 42 1.53798 7.2 14.3 
2 11.1318 42 1.60113 7.2 14.2 
3 10.9167 42 1.57231 7.2 14.9 
4 10.9350 40 1.38408 7.4 14.6 
5 11.1921 38 1.25383 8.2 13.5 
6 11.2972 36 1.92628 8.1 14.8 
Total 11.0665 245 1.54600 7.2 14.8 
Table 10. Means of hemoglobin for each month during the six month follow-ups 
7.3 Comparative statistics 
7.3.1 Evolution of hemoglobin 
Since hemoglobin fits normal distribution we compared the six month results globally using 
ANOVA with the result that no significant difference could be found (F=0.394, p=0.853).  
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To avoid possible errors due to sample size we have also used a nonparametric test 
(Kruskall-Wallis) with the same result: no significant difference (Chi square 1.473, p = 0.920). 
Median of hemoglobin and dispersion are represented as box plot on Fig. 5. 
MONTH
CFEDBA
H
b
15,00
10,00
5,00
0,00
168 238
179
55
147
43
 
Fig. 5. Box-Plot of the evolution of Hb during the 6 months of dialysis. Outliers are 
identified with the sample number. Checking the table data we observe that all these 
extreme values come from different patients.  
 
Fig. 6. Individual evolution of the six patients with extreme values. The vertical axis shows 
the values of hemoglobin (g / dl). The X axis shows the months of observation from A (first) 
to F (sixth). Patient 2 was excluded from the trial in the fourth month when the patient had a 
transplant. Patients 3 and 4 remained below 10g/dl of hemoglobin for most of the 
observation period. None of the patients exceeded 15 g/dl of hemoglobin. 
Fig. 7 shows the mean hemoglobin concentration month by month and the error bars for 
95% interval of confidence. The means remain in the range 10.9-11.3 g/dl. No significant 
differences with parametric methods (ANOVA, Student) and nonparametric (Kruskall –
Wallis and Mann-Witney)  
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Fig. 7. Mean hemoglobin month by month. Error bars indicate confidence intervals of 95% 
7.3.2 Patients with hemoglobin less than 11g/dl compared with those with hemoglobin 
≥ 11g/dl 
In this section we look for differences between the variables using a cutoff of 11 g/ dl of 
hemoglobin. Cases above and below this cutoff are almost balanced (n =117 (47.8%) 
<11g/dl) and n= 128 (52.2%≥ 11g/dl))  
The homogenization of variances tested detected 5 variables with significant differences; 
therefore we applied robust tests to avoid false results due to bias. The table 11 shows the 
results. 
 
Statistic 
F Sig. 
Statistic 
Welch 
 
Sig. 
CRP 4.629 .032 4.416 .037 
RET 1.597 .208 1.584 .209 
Fe 22.626 .000 23.323 .000 
TRANSF .760 .384 .732 .393 
FOLIC-INTRA .441 .507 .435 .510 
TSAT 24.433 .000 24.665 .000 
Log EPO 14.840 .000 14.479 .000 
Log IL-6 9.970 .002 9.813 .002 
Log FERRITINE .862 .354 .834 .362 
Log sTfR 1.316 .252 1.296 .256 
Log B12 .124 .725 .122 .727 
Log FOLIC .013 .908 .013 .909 
SRTf/logFERR .179 .672 .102 .751 
Table 11. Homohenization of variances test using a hemoglobin cutoff of 11g/dl. 
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Table 12 shows the means and standard error of the variables split by an 11g/dl hemoglobin 
cut-off. 
 Mean Std. Error Count p (Welch) 
EPO, Hb<11g/dl 32,316 5,245 117  
EPO, Hb>11 15,563 1,841 128 .000 
iIL-6, Hb<11g/dl 21,233 4,972 117  
iIL-6, Hb>11 10,037 1,512 128 .002 
RCP, Hb<11g/dl 2,742 ,547 115  
RCP, Hb>11 1,406 ,324 128 .037 
Hb, Hb<11g/dl 9,850 ,089 117  
Hb, Hb>11 12,178 ,094 128 .000 
RETIC, Hb<11g/dl 71,695 2,413 116  
RETIC, Hb>11 75,737 2,119 128 .209 
Fe, Hb<11g/dl 47,936 1,661 116  
Fe, Hb>11 61,136 2,171 128 .000 
TRANSFERRIN, Hb<11g/dl 176,270 3,843 116  
TRANSFERRIN, Hb>11 172,369 2,454 128 .393 
FERRITINE, Hb<11g/dl 412,477 32,283 116  
FERRITINE, Hb>11 388,068 20,490 128 .362 
sRTf, Hb<11Hb/dl 1,834 ,065 116  
sRTf, Hb>11 1,883 ,045 128 .256 
B12, Hb<11g/dl 543,487 23,179 117  
B12, Hb>11 539,320 18,008 128 .727 
FOLIC, Hb<11g/dl 30,862 5,583 117  
FOLIC, Hb>11 24,491 4,362 128 .909 
FOLIC-INTRA, Hb<11g/dl 734,179 77,436 117  
FOLIC-INTRA, Hb>11 668,572 62,481 127 .510 
sRTf:logF, Hb<11g/dl ,755 ,028 116  
sRTf:logF, Hb>11 ,761 ,021 128 .751 
TSAT, Hb<11g/dl 27,914 1,068 116  
TSAT, Hb>11 35,596 1,119 128 .000 
Table 12. Means and standard error of the variables split by an 11g/dl hemoglobin cut-off. 
7.3.3 Multiple linear regression 
Since there is no significant difference in monthly hemoglobin we handle all the data 
together. The dependent variable is hemoglobin and the rest explicative. The hematocrit was 
excluded because it is obviously closely related to hemoglobin. For variables that do not fit 
the normal distribution we made a logarithmic transformation. The method used is forward 
stepwise multiple linear regression. In the resulting model only three variables remain: 
serum iron, log soluble transferrin receptor and log EPO. Note that the correlation 
coefficient of the latter is negative. 
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Model   
Not standardized 
coefficients 
Standardized 
coefficients 
t Sig. 
 Steps   
B 
Standard 
error 
Beta zero-order Partial 
1 (constant) 10.109 .251   40.321 .000 
  Fe .018 .004 .259 4.179 .000 
2 (constant) 9.267 .334   27.765 .000 
  Fe .021 .004 .307 4.960 .000 
  Log sRTf 2.672 .721 .229 3.705 .000 
3 (constant) 
(Intercept) 
10.396 .413   25.167 .000 
  Fe .018 .004 .261 4.301 .000 
  Log sRTf 3.603 .728 .309 4.952 .000 
  Log EPO -1.053 .241 -.274 -4.363 .000 
Dependent variable: Hb 
Table 13. Forward step-wise multiple regression model. (Dependent variable hemoglobin) 
 
Fig. 8. Serum iron (mg/dl) and transferrin saturation (%) (TSAT). The central horizontal line 
plots the normal transferrin saturation of 30%. All means are above this line except for the 
sixth month. Nevertheless the latter is 28.6%, well above 20%. Error bars show the 
confidence interval 95%. 
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8. Iron, transferrin and saturation 
Fig. 8. shows the serum iron and transferrin saturation for each of the six months of 
observation. The error bars show confidence intervals of 95%. All media, with their 
respective confidence intervals are in the field of 30% saturation of transferrin, enough for 
an adequate iron supply to erythroblasts. However, some individual values are below those 
desirable. Specifically, 33 cases (14.2%) have transferrin saturation less than 20%. 
8.1 Ferritin 
Descriptive statistic for ferritin split by months is shown in table 14. 
 Mean Std. Dev. Std. Error Count Minimum Maximum 
FERRITIN. Total 399.672 292.319 18.714 244 33.200 2290.000 
FERRITIN. A 425.107 325.013 48.450 45 39.900 1952.000 
FERRITIN. B 378.284 249.318 37.586 44 33.200 1314.900 
FERRITIN. C 416.134 247.962 38.725 41 42.600 1159.100 
FERRITIN. D 376.029 317.108 50.139 40 49.400 1940.000 
FERRITIN. E 371.563 219.388 35.589 38 40.000 972.400 
FERRITIN. F 431.210 382.965 63.827 36 109.700 2290.000 
Table 14. Evolution of ferritin during the observation period. Consecutive months are 
represented by A to F. 
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Fig. 9. Mean ferritin (green bars) and transferrin saturation (TSAT) (blue bars). The latter has 
been multiplied by 10 to fit in the graph better.  
www.intechopen.com
 
Iron Metabolism 
 
116 
Mean ferritin is above 300 ng/ml in all cases. This does not necessarily mean that iron stores 
are adequate, as in renal failure and in other chronic diseases ferritin does not measure iron 
stores accurately. In 40 cases, the ferritin is less than 100 ng/ ml. In one case ferritin is above 
2.000 ng/ dl and in six cases over 1.000. The standard deviation is high because ferritin does 
not fit a normal distribution.  
8.2 Soluble transferrin receptor and soluble transferrin receptor/log ferritin index 
Fig. 10. shows the evolution of soluble Transferrin Receptor 
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Fig. 10. Evolution of soluble Receptor of Transferrin 
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Fig. 11. Evolution of sTfR / Log Ferritin index.  
9. Conclusions 
9.1 Predictors of response to therapy 
ANOVA shows significant differences between responders and non-responders for 
hemoglobin, hematocrit, red blood cells, erythropoietin, MCHC and Maf). Nevertheless only 
Hemoglobin (or red blood cells), EPO and MCHC were found to be the best predictors of 
response by multiple regression. However, the AUC of the ROC curves of each of these 
parameters separately is low and therefore its clinical utility is weak. The combination of red 
blood cells, erythropoietin and MCHC results in a mathematical model that significantly 
improves the predictive value of each of these variables, with an AUC of 0.72. (95% 
Confidence Interval: 0.62-0.80). The mathematical model is: 
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(3) 
This model does not improve with the inclusion of additional variables and has the 
advantage that it only includes routine analytical data, without sophisticated tests. The 
statistical procedure that we have described (factorial analysis, data reduction, logistic 
regression and ROC curves) may be a useful tool for future studies with more patients and 
longer observation which may improve the accuracy of prediction of response. 
9.2 Efficacy and safety 
9.2.1 Hemoglobin 
The mean hemoglobin level for the whole period of observation is X = 11.07g/dl; (SD 1.546; 
n = 245). When comparing the mean hemoglobin of each month, there are no significant 
differences and the small differences that are shown have no clinical significance. Therefore, 
the hemoglobin remains stable throughout the observation period with a mean within the 
desired range. Only six cases have been detected with extreme values (Box-Plot). None of 
the patients exceeded hemoglobin 15g/dl, and only two patients had hemoglobin levels 
persistently below 10g/dl. The cases above and below 11g/dl of hemoglobin are almost 
balanced (n =117 (47.8%) <11g/dl) and n= 128 (52.2%≥ 11g/dl)). These data confirm that this 
protocol maintains stable hemoglobin levels in the planned target. Achieved hemoglobin 
levels are somewhat lower than those recommended in the latest revision of K-DOKI clinical 
guidelines (KDOQI 2007), but conform to those recommended by others (Coyne 
2010)(Akizawa et al. 2008). 
When applying a cutoff of 11g/dl of hemoglobin there are significant differences above and 
below this value for the following parameters: C-reactive protein, serum iron, transferrin 
saturation, erythropoietin, and interleukin 6 (univariate analysis).  
The stepwise multiple regression (with hemoglobin as the dependent variable), allowed us 
to develop a model in which, in the final step, only three parameters remain: serum iron, 
transferrin soluble receptor and erythropoietin (the latter with a negative beta coefficient). In 
this model the constant is 10.396 and the standardized beta coefficients: iron (0.261), log 
soluble transferrin receptor (0.309) and log erythropoietin (-0.274). 
9.2.2 Iron 
Means and standard deviations of the variables that establish the status of iron are as 
follows: serum iron 54.86 ± 22.59, transferrin 174.22 ± 34.89, transferrin saturation 31.94 % ± 
12.70, ferritin 399.67 ± 292.31 and soluble transferrin receptor 1.86 ± 0.61. No significant 
differences were detected for these variables when comparing different months of 
observation.  
Of these variables only the mean serum iron is significantly different (p <0.001) in cases with 
hemoglobin less than 11g/dl (x = 47.93) than in cases with more than 11g/dl hemoglobin  
(x = 61.14). 
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Although the mean transferrin saturation of each month is in the desired range, 33 cases 
(14.2%) had a transferrin saturation of less than 20%. 
The mean index of transferrin soluble receptor / log ferritin is 0.7579 (above the 0.6 cut-off 
for iron deficiency) and the frequency distribution shows that 73.8% of the cases are above 
0.6. These cases are likely to have iron deficiency, according to.(Chen, Hung, and Tarng 
2006b) 
Although the mean transferrin soluble receptor is 1.856 mg/L (less than 2 mg/L cut-off for 
iron deficiency), 37.2% had levels above 2 mg/L. These cases are likely to have iron 
deficiency, according to (Chang et al. 2007) 
Therefore some patients have had iron deficiency at least once during the observation 
period in an amount ranging between 14.2% and 73.8%, depending on whether we use a less 
or more sensitive indicator. 
Therefore, the iron dose should be increased slightly to maintain deposits and availability of 
iron in adequate quantity for normal erythropoiesis. 
10. Discussion 
Predictors of response reported so far are : albumin (Agarwal, Davis, and Smith 2008), 
clinical factors (Bamgbola, Kaskel, and Coco 2009) , (Bistrian and Carey 2000), protocol 
adherence(Chan et al. 2009), soluble receptor of transferrin (Chang et al. 2007; Chen, Hung, 
and Tarng 2006a), low iron stores (low ferritin and low transferrin saturation), malnutrition, 
hyperparathyroidism, and high-turnover bone disease (Kalantar-Zadeh et al. 2009). 
In our model hypo-response to combination therapy with erythropoietin and iron occurs in 
patients with higher hemoglobin (11.4 in non-responders, versus 10.7 in responders), lower 
serum erythropoietin (11 in non-responders versus 18.4 in responders), higher MCHC (32.7 
in non-responders versus 32.3 in responders). To our knowledge this is the first time that 
MCHC is included in a model to predict response to combination therapy with 
erythropoietin and iron in anemia in hemodialysis patients. 
The difference in mean MCHC between responders and non-responders is marginal, but 
statistically significant.  
It may seem odd that a higher level of hemoglobin is a predictor of no response, but can be 
explained by the fact that a level equal to or greater than 12g/dl hemoglobin involves a 
reduction of 50% of the dose of erythropoietin, according to our protocol. In a patient with 
chronic renal failure on hemodialysis serum erythropoietin level depends largely on that 
which is administered as a drug because the endogenous secretion is strongly suppressed. 
Of the three variables in the model, the serum erythropoietin is the most easily adjustable in 
the short term, since it can be achieved by increasing the dose. Although our protocol has 
been shown effective in maintaining a stable mean hemoglobin level of 11g/dl, it is 
insufficient to achieve the target of 12 g/ dl recommended in the latest revision of the K-
DOKI guideline (KDOQI 2007). This trial had been designed before the amendment was 
published. Taking this into account it would be necessary to review the criteria for 
erythropoietin dose reduction conditioned by the level of hemoglobin. The importance of 
maintaining stable hemoglobin levels has been previously highlighted (Zaoui et al. 2011) 
www.intechopen.com
 
Iron Metabolism 
 
120 
(Mathieu et al. 2008). The last authors describe a cohort of patients in Switzerland with 
stable hemoglobin levels, although slightly higher (mean hemoglobin 11.9 g/dl), than those 
presented in this paper.  
Hemoglobin levels above 13g/dl, although recommended in some instances, have been 
associated with increased mortality. Recently, this increased mortality has been attributed to 
thrombocytosis induced by iron deficiency and therefore appropriate doses of intravenous 
iron could counteract the adverse effect of high doses of erythropoietin (Kalantar-Zadeh et 
al. 2009). However thrombocytosis associated with erythropoietin treatment to achieve high 
levels of hemoglobin can be attributed not only to iron deficiency but also to high doses of 
erythropoietin (Vaziri 2009).These data should be confirmed before raising the target 
hemoglobin level. 
In the last decade hematological cell counters provide new erythrocyte and reticulocyte cell 
indices that are useful for the differential diagnosis of anemia. Some of these indices could 
be useful to establish the status of iron metabolism in the anemia of patients with advanced 
renal disease on hemodialysis and to predict response to treatment. If confirmed, the CBC 
would provide data that would spare more expensive laboratory tests. Unexpectedly, the 
best predictor in terms of this work is MCHC, an erythrocyte index of routine, instead of the 
most innovative. In general the red cell indices were used to assess the iron status rather 
than as predictors of response. Each author recommends the ones they have examined, but 
there is no consensus because the results are variable and generally not confirmed. Some of 
these indices are: reticulocyte hemoglobin equivalent (Ret He) (Brugnara, Schiller, and 
Moran 2006), serum soluble transferrin receptor (Chang et al. 2007), transferrin receptor-
ferritin index (Chen, Hung, and Tarng 2006a), Soluble transferrin receptor and sTfR-F index 
(Choi 2008), soluble transferrin receptor and mean corpuscular hemoglobin (Choi 2007), as 
we have discussed in more detail in the introduction. 
The serum iron is an infrequently used index of iron deficiency. In general, low serum iron 
is unreliable as a marker of iron deficiency because of the wide variation throughout the 
day. Transferrin saturation is generally preferred because in the case of iron deficiency, 
serum transferrin increases while serum iron decreased; but this is not the case in chronic 
renal failure in which both values decrease in parallel and thus the transferrin saturation 
shows little variation. In our patients the standard deviation of serum iron, expressed in 
percentage is 41%, while the same variation for transferrin is only 20%. Despite such a high 
dispersion, serum iron enters the multiple regression model, while transferrin saturation 
does not. Moreover serum iron is the only indicator of iron status with significant mean 
difference when applying a cutoff of 11g/dl hemoglobin. Therefore, although the serum 
iron is not a good indicator of iron status at the individual level, it may be useful in clinical 
trials. 
Therefore we believe that serum iron should be taken into account in the case of anemia of 
chronic kidney disease. 
It is not easy to compare our results with others because the treatment protocol and 
response criteria are different. Moreover there are no randomized clinical trials designed to 
look for safety of treatment with intravenous iron in the long term and it is unclear which of 
the two trends are correct: Increasing the dose of iron to save erythropoietin, or increasing 
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the dose of erythropoietin to diminish the possible adverse effects of iron (Coyne 2010). The 
dilemma is important because high doses of erythropoietin also produce adverse effects. 
The most clear demonstration that increasing the number of patients treated with iron 
results in a decrease in erythropoietin dose in daily clinical practice (not only in clinical 
trials) are shown in the data published by (Hasegawa et al. 2011) . Although the balance 
between iron and erythropoietin therapy is still subject to discussion, it is clear that the 
combination therapy with both drugs reduce morbidity, mortality, hospital admissions and 
costs (Knight et al. 2010). 
In the present trial initial iron dose is 100 mg three times a week intravenously at the end of 
dialysis. The initial dose of erythropoietin is 40 U / K (2,800 U for a person of average 
weight 70K) three times a week.  
In a longitudinal study with data collected in Japan between 1999 and 2006 weekly doses of 
iron (160 mg / month) and erythropoietin (5531 U / week) are lower, but it must also be 
considered that the mean hemoglobin level was lower (10.4 g / dl )(Akizawa et al. 2008). 
(Charytan et al. 2001) using a schedule similar to ours (iron sucrose injection administered 
as 1,000 mg in 10 divided doses by IV push) concludes that this therapy is safe and effective 
for the treatment of iron deficiency in patients with dialysis-associated anemia. 
Iron Sucrose is the most widely iron used in patients with chronic kidney disease, but iron 
dextran of low molecular weight is equally effective (Atalay et al. 2011). 
Several trials compare the costs and effectiveness of treatment of classical formulations of 
iron and erythropoietin with the new ones (some not yet approved for kidney patients) 
(Bhandari 2011)(Cuesta Grueso et al. 2010). Although the efficacy of these new drugs is 
similar to the former ones, there is no conclusive evidence to justify the increased cost of 
new formulations of iron and erythropoietin. In one study ferric carboxymaltose was 
effective in increasing the mean level of hemoglobin from 9.1 to 10.3 g / dl, but at the 
expense of 7.4% of serious adverse effects (Covic and Mircescu 2010). Of the new iron 
preparations only isomaltose iron at doses between 600 and 1,000 mg is cost effective 
compared with iron dextran (Bhandari 2011). 
A comparative study was carried out: one branch with intravenous iron sucrose and the 
other with oral iron succinate. Both showed a positive response but the first one 
demonstrated better results. Although erythropoietin dose was lower in the intravenous 
iron branch, the total cost of both drugs together was higher. Gastrointestinal adverse events 
were higher in the oral branch (Li and Wang 2008). 
Several reports have found that the detection and early treatment of anemia of chronic 
kidney disease with erythropoiesis-stimulating agents improves the quality of life, including 
cognitive and physical performances: memory, sustain attention, energy level, work 
capacity, aerobic capacity, and immune function (Fishbane 2010).  
The alternative to transfusions most often used in patients with anemia of chronic kidney 
disease is erythropoietin and intravenous iron. Combination therapy is even more important 
in patients with anemia and cardio renal disease (Silverberg et al. 2009; Silverberg 2011; 
Silverberg 2010; Silverberg et al. 2010). 
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More than 90 % of end renal disease patients maintained on dialysis respond to traditional 
recombinant human erythropoietin (rHU EPO) or to EPO analogues (biosimilars, 
biogenerics) (Schmid and Schiffl 2010). 
The therapeutic dose of EPO are higher than normal endogenous rates of EPO production in 
healthy subjects, and the amount of IV-iron given may be greater than the amount needed 
for normal erythropoiesis. This increase in erythropoietin and iron needs may be due to 
chronic inflammation and vitamin C deficiency, present in many patients with chronic 
kidney disease (Handelman 2007). The comparison between clinical trials is difficult not 
only for the selection of patients and the different doses of erythropoietin and iron, but also 
for the management of chronic inflammation and replacement of folic acid and vitamins B12 
and C, data that are not always specified.  
The doses of erythropoietin should be considered together with hemoglobin levels and 
resistance to treatment and comorbidities. In patients with chronic renal failure, without 
mention of heart disease, adverse effects are associated with low levels of hemoglobin (<9.5 
g/ dl) despite high doses of erythropoietin (Bradbury et al. 2009), or with therapeutic targets 
of high hemoglobin levels (13.5 to 15 g / dl)(Belonje, de Boer, and Voors 2008) . In patients 
with simultaneous kidney and heart failure, erythropoietin improves cardiac function, even 
if it fails to raise the level of hemoglobin (Belonje, de Boer, and Voors 2008) (Pappas et al. 
2008). To understand the role of erythropoietin it should be noted that its physiological 
effects are beyond the stimulation of erythropoiesis (Diskin et al. 2008). 
Darbepoetin is as effective as epoetin alpha, but at a higher cost (Cuesta Grueso et al. 2010).  
A possible way to save costs would be to give biosimilar erythropoietin rather than original. 
A clinical trial has demonstrated the equivalence of Eprex with GerEpo (biogeneric) in the 
short term, but the short duration of the trial (12 weeks) did not provide any conclusions 
about safety (Goh et al. 2007). 
The current status of new anti-anemic drugs, including their indications and license in 
Europe and USA can be found in (Macdougall and Ashenden 2009). New intravenous iron 
preparations seem promising (Ferumoxytol), as well as erythropoietin with prolonged effect 
(CERA) and peptides that stimulate erythropoiesis by a mechanism different from 
erythropoietin (Hematide). Clinical trials are needed to establish the usefulness of these new 
drugs in patients with chronic kidney disease. 
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